OR WAIT null SECS
Hydra Biosciences enters into an agreement with Boehringer Ingelheim to research and develop small-molecule TRP inhibitors for renal diseases and disorders.
Hydra Biosciences announced on Apr. 13, 2015 that it entered into a research collaboration and license agreement with Boehringer Ingelheim to identify small-molecule transient receptor potential (TRP) inhibitors focused on the treatment of renal diseases and disorders. As part of the agreement, Boehringer Ingelheim will take responsibility for global development and commercialization of the TRP inhibitors that come from the collaboration. The financial details of the agreement were not disclosed, however, Hydra will receive an upfront payment, additional funding for research, and will be eligible to receive milestone payments and tiered royalty payments depending on product sales.
“This partnership between Boehringer Ingelheim and Hydra Biosciences provides an excellent opportunity to maximize the potential of novel targets that may offer meaningful improvements in the treatment of chronic kidney diseases and other related diseases and disorders. Boehringer Ingelheim’s long track record of research, development and commercialization success makes them the perfect partner for this program,” said Russell Herndon, president and CEO of Hydra Biosciences, in a press release.
Source: Hydra Biosciences